These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22201766)

  • 1. Enhancing graft-versus-leukemia after transplant: the rise of anti-cancer vaccines.
    Brusic A; Wu CJ
    Front Biosci (Landmark Ed); 2012 Jan; 17(2):635-55. PubMed ID: 22201766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer vaccines and T cell therapy.
    Rezvani K; Brody JD; Kohrt HE; Logan AC; Advani R; Czerwinski DK; Weng WK; Negrin RS; Carlton V; Faham M; Levy R; Barrett J
    Biol Blood Marrow Transplant; 2013 Jan; 19(1 Suppl):S97-S101. PubMed ID: 23041602
    [No Abstract]   [Full Text] [Related]  

  • 4. NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.
    Miller JS; Warren EH; van den Brink MR; Ritz J; Shlomchik WD; Murphy WJ; Barrett AJ; Kolb HJ; Giralt S; Bishop MR; Blazar BR; Falkenburg JH
    Biol Blood Marrow Transplant; 2010 May; 16(5):565-86. PubMed ID: 20152921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.
    Rezvani K; Barrett AJ
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):437-53. PubMed ID: 18790448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions.
    Krieger E; Toor AA
    Front Immunol; 2020; 11():777. PubMed ID: 32425947
    [No Abstract]   [Full Text] [Related]  

  • 9. T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect.
    Zhou M; Sacirbegovic F; Zhao K; Rosenberger S; Shlomchik WD
    Nat Commun; 2020 Aug; 11(1):4227. PubMed ID: 32839441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flow cytometric analysis of the graft-versus-Leukemia-effect after hematopoietic stem cell transplantation in mice.
    Schmidt F; Hilger N; Oelkrug C; Svanidze E; Ruschpler P; Eichler W; Boldt A; Emmrich F; Fricke S
    Cytometry A; 2015 Apr; 87(4):334-45. PubMed ID: 25717029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect.
    Sprangers B; Van Wijmeersch B; Fevery S; Waer M; Billiau AD
    Nat Clin Pract Oncol; 2007 Jul; 4(7):404-14. PubMed ID: 17597705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell therapy of leukemia.
    Riddell SR; Murata M; Bryant S; Warren EH
    Cancer Control; 2002; 9(2):114-22. PubMed ID: 11965232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies.
    Warren EH; Deeg HJ
    Tissue Antigens; 2013 Apr; 81(4):183-93. PubMed ID: 23510414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.
    Liu J; Zhang X; Zhong JF; Zhang C
    Immunotherapy; 2019 Jan; 11(1):37-44. PubMed ID: 30702011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding and enhancing the graft-versus-leukemia effect after hematopoietic stem cell transplantation.
    Molldrem J; Riddell S
    Cancer Treat Res; 2009; 144():187-208. PubMed ID: 19779869
    [No Abstract]   [Full Text] [Related]  

  • 16. T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation.
    Schetelig J; Kiani A; Schmitz M; Ehninger G; Bornhäuser M
    Cancer Immunol Immunother; 2005 Nov; 54(11):1043-58. PubMed ID: 15887014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions.
    Piesche M; Ho VT; Kim H; Nakazaki Y; Nehil M; Yaghi NK; Kolodin D; Weiser J; Altevogt P; Kiefel H; Alyea EP; Antin JH; Cutler C; Koreth J; Canning C; Ritz J; Soiffer RJ; Dranoff G
    Clin Cancer Res; 2015 Mar; 21(5):1010-8. PubMed ID: 25538258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell optimization for graft-versus-leukemia responses.
    Biernacki MA; Sheth VS; Bleakley M
    JCI Insight; 2020 May; 5(9):. PubMed ID: 32376800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding and harnessing the graft-versus-leukaemia effect.
    Barrett AJ
    Br J Haematol; 2008 Sep; 142(6):877-88. PubMed ID: 18564358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of leukemia relapse after allogeneic hematopoietic stem cell transplantation: integrating transplantation with genetically modified T cell therapies.
    Dotti G
    Curr Opin Hematol; 2015 Nov; 22(6):489-96. PubMed ID: 26335421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.